Osimertinib, for instance, has obtained approval from both the American regulatory agency, the USFDA, and the European regulatory agency, the European Medicines Agency (EMA), for its utilization in the treatment of patients diagnosed with metastatic EGFR T790 M NSCLC [24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.